Article | Published:

Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations

Abstract

Purpose

Noninvasive prenatal screening (NIPS) for fetal aneuploidy via cell-free DNA has been commercially available in the United States since 2011. In 2016, the American College of Medical Genetics and Genomics (ACMG) issued a position statement with specific recommendations for testing laboratories. We sought to evaluate adherence to these recommendations.

Methods

We focused on commercial laboratories performing NIPS testing in the United States as of 1 January 2018. Sample laboratory reports and other materials were scored for compliance with ACMG recommendations. Variables scored for common and sex chromosome aneuploidy detection included detection rate, specificity, positive and negative predictive value, and fetal fraction. Labs that performed analysis of copy-number variants and results for aneuploidies other than those commonly reported were identified. Available patient education materials were similarly evaluated.

Results

Nine of 10 companies reported fetal fraction in their reports, and 8 of 10 did not offer screening for autosomal aneuploidies beyond trisomy 13, 18, and 21. There was inconsistency in the application and reporting of other measures recommended by ACMG.

Conclusions

Laboratories varied in the degree to which they met ACMG position statement recommendations. No company adhered to all laboratory guidance.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Global non-invasive prenatal testing and newborn screening market, 2017-2027. https://www.prnewswire.com/news-releases/global-non-invasive-prenatal-testing-and-newborn-screening-market-2017-2027-300479661.html. Accessed 24 October 2018.

  2. 2.

    Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18:1056–1065.

  3. 3.

    Committee on Practice Bulletins—Obstetrics, Committee on Genetics, and the Society for Maternal-Fetal Medicine. Practice bulletin no. 163: screening for fetal aneuploidy. Obstet Gynecol. 2016;127:e123–137.

  4. 4.

    Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns. 2013;22:291–295.

  5. 5.

    Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2015;35:725–734.

  6. 6.

    Glenn EP, Robert GB. Sequencing cell-free DNA in the maternal circulation to screen for down syndrome, other common trisomies, and selected genetic disorders. In: Netto GJ, Kaul KL, Best, BPG, eds. Genomic Applications in Pathology. 2nd ed. 2019 edition. New York, NY: Springer; 2018. p. 721–749.

  7. 7.

    Nelson Goff BS, Springer N, Foote LC, et al. Receiving the initial Down syndrome diagnosis: a comparison of prenatal and postnatal parent group experiences. Intellect Dev Disabil. 2013;51:446–457.

  8. 8.

    Levis DM, Harris S, Whitehead N, Moultrie R, Duwe K, Rasmussen SA. Women’s knowledge, attitudes, and beliefs about Down syndrome: a qualitative research study. Am J Med Genet A. 2012;158A:1355–1362

  9. 9.

    Skotko BG, Kishnani PS, Capone GT, Down Syndrome Diagnosis Study Group. Prenatal diagnosis of Down syndrome: how best to deliver the news. Am J Med Genet A. 2009;149A:2361–2367.

  10. 10.

    Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370:799–808.

  11. 11.

    Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372:1589–1597.

  12. 12.

    Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol. 2015;45:530–538

  13. 13.

    Takoudes T, Hamar B. Performance of non-invasive prenatal testing when fetal cell-free DNA is absent. Ultrasound Obstet Gynecol. 2015;45:112.

  14. 14.

    Pergament E, Cuckle H, Zimmermann B, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014;124:210–218.

  15. 15.

    Deans ZC, Allen S, Jenkins L, et al. Recommended practice for laboratory reporting of non‐invasive prenatal testing of trisomies 13, 18 and 21: a consensus opinion. Prenat Diagn. 2017;37:699–704.

Download references

Acknowledgements

The authors would like to thank Judith Benkendorf for her early assistance with this research.

Author information

Disclosure

Financial conflicts of interest: B.G.S. occasionally consults on the topic of Down syndrome (DS) through Gerson Lehrman Group. He receives remuneration from DS nonprofit organizations for speaking engagements and associated travel expenses. B.G.S. receives annual royalties from Woodbine House, Inc., for the publication of his book, Fasten Your Seatbelt: A Crash Course on Down Syndrome for Brothers and Sisters. Within the past 2 years, B.G.S. has received research funding from F. Hoffmann–La Roche, Inc. to conduct clinical trials on study drugs for people with DS. B.G.S. is occasionally asked to serve as an expert witness for legal cases where DS is discussed. M.W.L. and S.M. are employees of the National Center for Prenatal & Postnatal Resources at the University of Kentucky, which produces and sells patient educational material recommended by professional guidelines; M.W.L. and S.M. receive no direct compensation from the sale of such materials. K.B. has financial holdings in GenomeSmart, a patient education platform. M.A.A. is an employee of Mayo Clinic, which provides cell-free DNA testing services through Mayo Medical Laboratories; M.A.A. receives no direct compensation from the sale of such tests. A.R.G. participated in the production of a continuing medical education (CME) activity on NIPT for Medscape. Other conflicts of interest: Beyond the items mentioned in the financial disclosures above, B.G.S. serves in a nonpaid capacity on the Honorary Board of Directors for the Massachusetts Down Syndrome Congress, the Board of Directors for the Band of Angels Foundation, and the Professional Advisory Committee for the National Center for Prenatal and Postnatal Down Syndrome Resources. B.G.S. has a sister with DS. M.W.L. serves in a nonpaid capacity on the D.S. Education Foundation for Down Syndrome of Louisville. M.W.L. has a daughter with DS. S.M. has a son with DS. S.K. and A.R.G. serve in a nonpaid capacity on the Board of Directors for the American College of Medical Genetics and Genomics (ACMG). A.R.G. also serves on the ACMG Foundation Board of Directors. M.A.A. has received travel funding compensation from the Association for X and Y Chromosome Variations. The other authors declare no conflicts of interest.

Correspondence to Brian G. Skotko MD, MPP.

Supplementary information

Supplementary Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • noninvasive prenatal tests
  • NIPT
  • noninvasive prenatal screens
  • NIPS
  • trisomy 21

Further reading